Participated · Equity · Feb 2022

NMD Pharma is a clinical-stage biotech spun off from Aarhus University that has developed a muscle electrophysiology platform and small-molecule modulators targeting the skeletal muscle chloride channel ClC-1. Led by CEO Thomas Holm Pedersen, the company focuses on discovering proprietary modulators of neuromuscular function using enabling technologies, in vivo pharmacology models, and muscle physiology know-how. Its lead program is NMD670, a ClC-1 inhibitor advancing into clinical trials. The company raised €75M in a Series B to fund near-term clinical development. Proceeds will be used to complete three Phase 2 studies evaluating NMD670 in AChR- and MuSK-antibody positive myasthenia gravis, spinal muscular atrophy, and Charcot–Marie–Tooth disease. NMD Pharma also plans to expand its pipeline of ClC-1 inhibitor molecules, pursue additional undisclosed neuromuscular targets, and grow its clinical and commercial operations in Denmark and the US. NMD Pharma is a Danish clinical-stage biotech focused on developing breakthrough therapies for patients with severe neuromuscular disorders. Its lead candidate, NMD670, is being developed to treat symptoms of Myasthenia Gravis, and the company maintains a CLC-1 inhibitor portfolio. NMD Pharma has built a platform and a high level of expertise specifically dedicated to the neuromuscular field. The company raised a €35 million financing led by Jeito Capital. The financing is intended to expand clinical programs into several neuromuscular diseases, including spinal muscular atrophy, grow the pipeline, and support expansion to new targets. Jeito Capital will also support market entry strategy and has joined the board to assist the company as it advances development toward patients.

Led · Series A · Mar 2019

SNIPR BIOME is a clinical-stage biotech in Copenhagen that leverages a novel application of CRISPR-Cas technology to treat and prevent human disease via precision killing of bacteria or gene modification. Its SNIPR technology is applied in collaborations with CARB-X, the Gates Foundation, the Cystic Fibrosis Foundation, IPATH, SPRIN‑D and MD Anderson Cancer Center. The company focuses on microbial CRISPR-medicine, with programs aimed at infectious-disease targets. Led by CEO Christian Grøndahl, SNIPR Biome is advancing CRISPR-based therapeutic approaches toward the clinic. The company recently completed a significant Series B raise, strengthening its balance sheet to continue development. It intends to use the new funds to support a CRISPR-Cas therapy specifically targeting airway infections caused by Pseudomonas aeruginosa in people with cystic fibrosis. SNIPR Biome is a Copenhagen-based clinical-stage biotech pioneering CRISPR-Cas–armed phages (CAPs) as precision medicines to prevent and treat bacterial infections and to modify microbiomes. The company has developed an existing CRISPR-armed phage cocktail, SNIPR001, comprising four CAPs that broadly target Escherichia coli and will leverage this in the new project. SNIPR draws from an extensive phage library with broad antibacterial activity against E. coli and Klebsiella pneumoniae strains sourced from sites in low- and middle-income countries (LMICs). SNIPR was the first company to orally dose humans with a CRISPR therapeutic and holds US and European patents for the use of CRISPR targeting microbiomes. The company works with collaborators including Novo Nordisk, CARB-X, SPRIN-D, and MD Anderson Cancer Center. With new Gates Foundation funding, SNIPR plans to develop microbiome-directed CAPs aimed at reducing gut entero-pathogen burden to improve environmental enteric dysfunction (EED) and pregnancy outcomes in LMICs. SNIPR Biome pioneers precision medicines using CRISPR/Cas for microbial gene therapy, focusing on designer phage and bacteria to edit or kill target microbes. Its lead product, SNIPR001, is a CRISPR-armed phage therapeutic that selectively targets E. coli in the gut and aims to prevent E. coli bloodstream infections in hematological cancer patients. Preclinical data published in Nature Biotechnology showed selective removal of antibiotic-resistant E. coli without off-target effects, and an interim Phase 1 in healthy subjects demonstrated safety, target engagement, and dose-dependent fecal recovery. SNIPR001 has received Fast-Track designation from the FDA for prophylaxis of bloodstream E. coli infections in patients with hematological malignancy at risk of neutropenia. The company collaborates with partners including Novo Nordisk, CARB-X, SPRIN-D, and MD Anderson, and states it was the first to orally dose humans with a CRISPR therapeutic and to obtain US and European patents for CRISPR targeting of microbiomes. The recent funding will support advancing SNIPR001 into patient trials and underpin a further significant fundraise to continue development of its AMR and gut-directed pipeline. SNIPR BIOME ApS is a CRISPR- and microbiome-biotechnology company based in Copenhagen, Denmark. Its lead candidate, SNIPR001, is being developed to prevent Escherichia coli infections in cancer patients, particularly those with hematological malignancies. The program aims to eradicate E. coli that can cause life-threatening bloodstream infections in patients weakened by disease and chemotherapy. SNIPR BIOME is advancing SNIPR001 through preclinical development under an award from CARB-X. The company may receive milestone-based additional funding tied to project progress. The work focuses on an engineered drug approach that leverages the company’s CRISPR and microbiome expertise. Snipr Biome is developing CRISPR-based therapeutics that use bacteria's CRISPR/Cas systems to selectively target and kill bacteria with defined DNA sequences. The company has secured a series of patents on altering microbiota for purposes including immune modulation. Snipr plans to advance its CRISPR microbiome drugs into clinical trials and has been refining its R&D strategy following technology validation. It will initially focus on precision medicines for difficult-to-treat infections and precision microbiome modulation in autoimmunity and cancer. The technology also has potential applications against multi-drug-resistant bacteria and in food-industry quality control. Snipr recently raised $50 million to support these development efforts.